Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EGRIFTA safety in HIV patients with diabetes and lipohypertrophy
NCT01591902Phase 4Terminated
- Sponsor
- Theratechnologies Inc.
- Start
- Jun 2012
- Primary completion
- May 2018
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 4 trial of tesamorelin in HIV-associated lipodystrophy (HALS), sponsored by Theratechnologies Inc.. Started Jun 2012; status: terminated.
02
Drugs
tesamorelin
03
Conditions
HIV-associated lipodystrophy (HALS)
Beyond the preview
Go deeper on NCT01591902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01591902.